NCT01821118 - Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Cerebral Amyloid Angiopathy

Interventions

BIOLOGICAL

Ponezumab

Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.

OTHER

placebo

placebo (saline)- given via infusion total infusion time of 20 minutes

Trial Locations (13)

10032

Columbia University, New York

59037

CHRU de Lille - Hôpital Roger Salengro, Lille

CHRU de Lille, Lille

63110

Barnes Jewish Hospital, St Louis

90095

UCLA Ronald Reagan Medical Center, Los Angeles

02114

MGH Stroke Research Center, Boston

02118

Boston Medical Center - Menino Pavilion, Boston

Boston Medical Center - Shapiro Center, Boston

02129

Anthinoula A. Martinos Center for Biomedical Imaging, Charlestown

T2N 2T9

University of Calgary/Foothills Medical Centre, Calgary

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

3584 CX

University Medical Center Utrecht, Utrecht

WC1N 3BG

University College of London, London